230 related articles for article (PubMed ID: 29906493)
1. The tamoxifen derivative ridaifen-B is a high affinity selective CB
Franks LN; Ford BM; Fujiwara T; Zhao H; Prather PL
Toxicol Appl Pharmacol; 2018 Aug; 353():31-42. PubMed ID: 29906493
[TBL] [Abstract][Full Text] [Related]
2. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.
Prather PL; FrancisDevaraj F; Dates CR; Greer AK; Bratton SM; Ford BM; Franks LN; Radominska-Pandya A
Biochem Biophys Res Commun; 2013 Nov; 441(2):339-43. PubMed ID: 24148245
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.
Ford BM; Franks LN; Radominska-Pandya A; Prather PL
PLoS One; 2016; 11(12):e0167240. PubMed ID: 27936172
[TBL] [Abstract][Full Text] [Related]
4. CB2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene.
Kumar P; Song ZH
Biochem Biophys Res Commun; 2014 Jan; 443(1):144-9. PubMed ID: 24275139
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.
Franks LN; Ford BM; Madadi NR; Penthala NR; Crooks PA; Prather PL
Eur J Pharmacol; 2014 Aug; 737():140-8. PubMed ID: 24858620
[TBL] [Abstract][Full Text] [Related]
7. Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity.
Franks LN; Ford BM; Prather PL
Front Pharmacol; 2016; 7():503. PubMed ID: 28066250
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development.
Shoeib AM; Yarbrough AL; Ford BM; Franks LN; Urbaniak A; Hensley LL; Benson LN; Mu S; Radominska-Pandya A; Prather PL
Life Sci; 2021 Nov; 285():119993. PubMed ID: 34592231
[TBL] [Abstract][Full Text] [Related]
10. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
Shoemaker JL; Joseph BK; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Aug; 314(2):868-75. PubMed ID: 15901805
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.
Iwamura H; Suzuki H; Ueda Y; Kaya T; Inaba T
J Pharmacol Exp Ther; 2001 Feb; 296(2):420-5. PubMed ID: 11160626
[TBL] [Abstract][Full Text] [Related]
15. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
17. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.
Qamri Z; Preet A; Nasser MW; Bass CE; Leone G; Barsky SH; Ganju RK
Mol Cancer Ther; 2009 Nov; 8(11):3117-29. PubMed ID: 19887554
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of (3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist.
Presley CS; Mustafa SM; Abidi AH; Moore BM
Bioorg Med Chem; 2015 Sep; 23(17):5390-401. PubMed ID: 26275680
[TBL] [Abstract][Full Text] [Related]
19. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.
Mulè F; Amato A; Baldassano S; Serio R
Pharmacol Res; 2007 Sep; 56(3):185-92. PubMed ID: 17656103
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands.
Ragusa G; Bencivenni S; Morales P; Callaway T; Hurst DP; Asproni B; Merighi S; Loriga G; Pinna GA; Reggio PH; Gessi S; Murineddu G
ChemMedChem; 2018 Jun; 13(11):1102-1114. PubMed ID: 29575721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
